Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

0.6920
-0.0204-2.86%
Post-market: 0.6815-0.0105-1.52%19:09 EDT
Volume:108.90K
Turnover:76.98K
Market Cap:3.18M
PE:-0.06
High:0.7300
Open:0.7200
Low:0.6803
Close:0.7124
52wk High:28.98
52wk Low:0.6803
Shares:4.60M
Float Shares:4.35M
Volume Ratio:0.07
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.3794
EPS(LYR):-37.5481
ROE:-705.71%
ROA:-127.92%
PB:0.64
PE(LYR):-0.02

Loading ...

Artelo Biosciences announces new ART26.12 data

TIPRANKS
·
Jul 16

Artelo Says Preclinical Osteoarthritis Study Shows Art26.12 Matches Naproxen Pain Relief with Less Gastric Damage

Reuters
·
Jul 16

Artelo Biosciences - to Begin Clinical Multiple Ascending Dose Study of Art26.12 in Q4

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting Art26.12 as a Potential First-in-class New Therapy for Chronic Pain Conditions

THOMSON REUTERS
·
Jul 16

Artelo Biosciences - Art26.12 Shows Efficacy Comparable to Naproxen in Nonclinical Osteoarthritis Study

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Artelo Biosciences Reports Positive Preclinical Data for Art27.13 in Paclitaxel-induced Peripheral Neuropathy Model

Reuters
·
Jul 13

Artelo Biosciences - Interim Results Show Improved Body Weight, Lean Mass, Activity, and Safety up to 1300 Μg/day

THOMSON REUTERS
·
Jul 13

Artelo Biosciences - Art27.13 Reduces Neuropathic Pain Behaviors in Paclitaxel-treated Animals

THOMSON REUTERS
·
Jul 13

SK Hynix's Landmark Nasdaq Debut Bets on AI Reshaping Memory Chip Industry's Boom-Bust Cycle

Deep News
·
Jul 11

SK hynix's $26.5 Billion Nasdaq Debut: A Test for Overcoming the 'Korea Discount'

Stock News
·
Jul 10

Artelo Biosciences presents preclinical pain data for ART26.12

TIPRANKS
·
Jul 01

Artelo Biosciences Reports Positive Preclinical Data for Art26.12 in Spinal Cord Injury Neuropathic Pain Model

Reuters
·
Jul 01

Artelo Biosciences Announces New Data Supporting Art26.12 as a Potential First-in-class Therapy for Chronic Pain Associated with Spinal Cord Injury

THOMSON REUTERS
·
Jul 01

Artelo Biosciences Says Phase 1 FABP5 Inhibitor Art26.12 Study Shows Linoleic Acid Signaling Link Across Disease Models

Reuters
·
Jun 30

Bitcoin Mining Firm Ionic Digital Files for Direct Listing on Nasdaq

Stock News
·
Jun 30

Artelo Biosciences Says Phase 1 Study Shows FABP5 Inhibitor Art26.12 is Well Tolerated, with Linear Pharmacokinetics

Reuters
·
Jun 29

Bank of America Issues Warning: Nasdaq Reaches "Bubble Threshold" Driven by Semiconductors

Deep News
·
Jun 25

U.S. Markets Open Mixed as Focus Turns to SpaceX Nasdaq Debut

Deep News
·
Jun 12

Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial

Reuters
·
Jun 10